Prudential Financial Inc. Boosts Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Prudential Financial Inc. increased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 62.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,488 shares of the company’s stock after buying an additional 36,983 shares during the period. Prudential Financial Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in TEVA. US Bancorp DE raised its position in Teva Pharmaceutical Industries by 6.5% during the first quarter. US Bancorp DE now owns 10,812 shares of the company’s stock worth $166,000 after acquiring an additional 656 shares during the period. MAI Capital Management increased its stake in shares of Teva Pharmaceutical Industries by 26.8% during the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after purchasing an additional 697 shares in the last quarter. Wedbush Securities Inc. increased its stake in shares of Teva Pharmaceutical Industries by 3.3% during the second quarter. Wedbush Securities Inc. now owns 21,995 shares of the company’s stock worth $369,000 after purchasing an additional 700 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Teva Pharmaceutical Industries by 15.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,474 shares of the company’s stock worth $92,000 after purchasing an additional 715 shares during the last quarter. Finally, CWM LLC lifted its stake in Teva Pharmaceutical Industries by 18.1% in the 2nd quarter. CWM LLC now owns 4,995 shares of the company’s stock valued at $84,000 after buying an additional 767 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $28.45 on Friday. The business’s 50 day moving average price is $22.48 and its 200 day moving average price is $19.17. The company has a market cap of $32.63 billion, a price-to-earnings ratio of 47.42, a PEG ratio of 1.53 and a beta of 0.67. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $28.68.

Insider Activity

In other news, Director Roberto Mignone sold 200,000 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the transaction, the director owned 495,000 shares in the company, valued at $11,934,450. The trade was a 28.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.49% of the stock is owned by company insiders.

Analysts Set New Price Targets

TEVA has been the subject of several research reports. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Scotiabank began coverage on Teva Pharmaceutical Industries in a research report on Friday. They set a “sector outperform” rating and a $35.00 price target for the company. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $27.00.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.